Discovery of (R)-8-(1-(3,5-Difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and PI3Kδ for the Treatment of PTEN-Deficient Cancers-Reference-Cited by-同舟云学术

Discovery of (R)-8-(1-(3,5-Difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and PI3Kδ for the Treatment of PTEN-Deficient Cancers

Published:2015-01-07 Issue:2 Volume:58 Page:943-962
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Barlaam Bernard¹,Cosulich Sabina¹,Degorce Sébastien¹,Fitzek Martina¹,Green Stephen¹,Hancox Urs¹,Lambert-van der Brempt Christine²,Lohmann Jean-Jacques²,Maudet Mickaël²,Morgentin Rémy²,Pasquet Marie-Jeanne²,Péru Aurélien²,Plé Patrick²,Saleh Twana²,Vautier Michel²,Walker Mike¹,Ward Lara¹,Warin Nicolas²

Affiliation:

1. Oncology iMed, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom

2. Centre de Recherches, AstraZeneca, Z. I. La Pompelle, Chemin de Vrilly, BP 1050, 51689 Reims Cedex 2, France

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm501629p

Reference55 articles.

1. Targeting the phosphoinositide 3-kinase pathway in cancer

2. The PI3K Pathway As Drug Target in Human Cancer